Texas Roadhouse reported a 6.2% same-store sales increase, driven by a 3% rise in customer traffic and average unit volumes near $9.5 million, exceeding expectations. The company benefits from disciplined pricing below inflation and improved gross margins due to favorable sirloin prices. However, management expects cost of goods sold inflation of 2-3% in Q3 and around 5% in Q4, cautioning that recent margin gains should not be annualized. The outlook remains positive with a 'Buy' rating and a $190 price target, supported by strong unit economics and growth potential as beef prices stabilize.
Texas Roadhouse stock and its recent performance provide context for consumer cyclical sector trends. For readers following this sector, here is Pluang's market snapshot as of Sep 17, 2026 18:51 WIB: of 105 priced Consumer Cyclical-sector US stocks tradable on Pluang, 89 rose and 12 fell today. Notable movers include Carvana Co (CVNA) at USD 66.61 with a 1-day change of +1.85%, Quantumscape Corp (QS) at USD 5.09 with +1.80%, and Macy's Inc (M) at USD 22.20 with +1.79%.
Particula has assigned a AAA-rating to WisdomTree Treasury Money Market Digital Fund (WTGXX), a $1.2 billion tokenized money market fund. The fund invests in short-term U.S. Treasury securities and government money market funds, aiming to preserve ca...
AlphaPepe's cryptocurrency presale has surpassed 12,500 holders and raised nearly $3 million before its first public exchange listing, signaling strong community growth. More than 100 new holders join daily, with a fifth centralized exchange (CEX) pa...
ZenaTech announced a 27.1% organic revenue growth in its Drone as a Service (DaaS) operations in 2026, driven by integrating AI and drones into surveying and inspection workflows. The company expects Q3 2026 revenues between C$13.4 million and C$14.8...
XRPL Commons has launched its ninth fully online Aquarium cohort, selecting 13 startups from 11 countries focused on expanding XRP Ledger applications beyond transfers. The startups develop solutions in stablecoin payments, AI-powered commerce, block...
Syndax Pharmaceuticals' stock fell more than 11% after its drug axatilimab failed to meet the primary endpoint in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF). The trial showed no benefit in lung function decline, leading Syndax to halt fu...
